These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1793782)

  • 1. Is topical therapy necessary in acute distal colitis? Double-blind comparison of high-dose oral mesalazine versus steroid enemas in the treatment of active distal ulcerative colitis.
    Cobden I; al-Mardini H; Zaitoun A; Record CO
    Aliment Pharmacol Ther; 1991 Oct; 5(5):513-22. PubMed ID: 1793782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis.
    Lee FI; Jewell DP; Mani V; Keighley MR; Kingston RD; Record CO; Grace RH; Daniels S; Patterson J; Smith K
    Gut; 1996 Feb; 38(2):229-33. PubMed ID: 8801202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis.
    Mantzaris GJ; Hatzis A; Petraki K; Spiliadi C; Triantaphyllou G
    Dis Colon Rectum; 1994 Jan; 37(1):58-62. PubMed ID: 8287749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
    Kam L; Cohen H; Dooley C; Rubin P; Orchard J
    Am J Gastroenterol; 1996 Jul; 91(7):1338-42. PubMed ID: 8677990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial.
    Friedman LS; Richter JM; Kirkham SE; DeMonaco HJ; May RJ
    Am J Gastroenterol; 1986 Jun; 81(6):412-8. PubMed ID: 3518408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis.
    Campieri M; Gionchetti P; Belluzzi A; Brignola C; Tampieri M; Iannone P; Miglioli M; Barbara L
    Gut; 1991 Aug; 32(8):929-31. PubMed ID: 1885075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of rectal formulations: enemas.
    Campieri M; Gionchetti P; Belluzzi A; Brignola C; Tampieri M; Iannone P; Petronelli A; Miglioli M; Barbara L
    Scand J Gastroenterol Suppl; 1990; 172():63-5. PubMed ID: 2353173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis.
    Willoughby CP; Piris J; Truelove SC
    Scand J Gastroenterol; 1980; 15(6):715-9. PubMed ID: 7010522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double-blind, placebo-controlled trial.
    Ginsberg AL; Beck LS; McIntosh TM; Nochomovitz LE
    Ann Intern Med; 1988 Feb; 108(2):195-9. PubMed ID: 3277506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.
    Safdi M; DeMicco M; Sninsky C; Banks P; Wruble L; Deren J; Koval G; Nichols T; Targan S; Fleishman C; Wiita B
    Am J Gastroenterol; 1997 Oct; 92(10):1867-71. PubMed ID: 9382054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial.
    Pullan RD; Ganesh S; Mani V; Morris J; Evans BK; Williams GT; Rhodes J
    Gut; 1993 May; 34(5):676-9. PubMed ID: 8504970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
    Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
    Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory distal ulcerative colitis responsive to 5-aminosalicylate enemas.
    Barber GB; Lee DE; Antonioli DA; Peppercorn MA
    Am J Gastroenterol; 1985 Aug; 80(8):612-4. PubMed ID: 2862789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized, double-blind study.
    Bianchi Porro G; Ardizzone S; Petrillo M; Fasoli A; Molteni P; Imbesi V
    Am J Gastroenterol; 1995 May; 90(5):736-9. PubMed ID: 7733079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.
    Sinha A; Nightingale J; West KP; Berlanga-Acosta J; Playford RJ
    N Engl J Med; 2003 Jul; 349(4):350-7. PubMed ID: 12878742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
    Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
    Green JR; Mansfield JC; Gibson JA; Kerr GD; Thornton PC
    Aliment Pharmacol Ther; 2002 Jan; 16(1):61-8. PubMed ID: 11856079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
    Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
    J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.